AN2 Therapeutics Ownership | Who Owns AN2 Therapeutics?

AN2 Therapeutics Ownership Summary

AN2 Therapeutics is owned by 4.50% institutional investors, 18.87% insiders, and 76.63% retail investors. Vivo capital is the largest institutional shareholder, holding 10.44% of ANTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.04% of its assets in AN2 Therapeutics shares.

ANTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	AN2 Therapeutics	4.50%	18.87%	76.63%
Sector	Healthcare Stocks	35.71%	11.88%	52.42%
Industry	Biotech Stocks	35.98%	11.86%	52.17%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vivo capital	3.15M	10.44%	$10.79M
Commodore capital lp	2.33M	7.72%	$7.98M
Millennium management	2.22M	7.36%	$7.60M
Almitas capital	1.48M	4.90%	$5.06M
Vanguard group	1.08M	3.57%	$1.23M
Adage capital partners gp	1.00M	3.31%	$3.42M
Woodline partners lp	993.67K	3.29%	$3.40M
Boxer capital management	749.03K	2.48%	$2.56M
Stonepine capital management	713.85K	2.36%	$2.44M
Ameriprise financial	696.18K	2.30%	$2.38M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Almitas capital	1.48M	1.14%	$5.06M
Stonepine capital management	713.85K	0.98%	$2.44M
Vivo capital	3.15M	0.90%	$10.79M
Commodore capital lp	2.33M	0.46%	$7.98M
Boxer capital management	749.03K	0.34%	$2.56M
Sio capital management	657.20K	0.32%	$2.25M
Prosight management, lp	515.75K	0.29%	$1.76M
Peapod lane capital	59.85K	0.17%	$206.90K
Landscape capital management	298.17K	0.06%	$1.02M
Persistent asset partners	38.16K	0.05%	$130.49K

Top Buyers

Holder	Shares	% Assets	Change
Vivo capital	3.15M	0.90%	3.15M
Commodore capital lp	2.33M	0.46%	2.33M
Millennium management	2.22M	0.00%	2.13M
Adage capital partners gp	1.00M	0.01%	1.00M
Woodline partners lp	993.67K	0.01%	847.70K

Top Sellers

Holder	Shares	% Assets	Change
Bml capital management	-	-	-5.75M
Octagon capital advisors lp	-	-	-3.22M
Frazier life sciences management	-	-	-2.09M
Ra capital management	-	-	-2.00M
Tcg crossover management	-	-	-1.56M

New Positions

Holder	Shares	% Assets	Change	Value
Vivo capital	3.15M	0.90%	3.15M	$10.79M
Commodore capital lp	2.33M	0.46%	2.33M	$7.98M
Adage capital partners gp	1.00M	0.01%	1.00M	$3.42M
Boxer capital management	749.03K	0.34%	749.03K	$2.56M
Ameriprise financial	696.18K	0.00%	696.18K	$2.38M

Sold Out

Holder	Change
Jpmorgan chase	-49.00
Wells fargo & company/mn	-128.00
Coldstream capital management	-783.00
Fmr	-1.20K
Highline wealth partners	-5.00K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	11	-70.27%	1,358,232	-84.32%	4	0.55%	8	-42.86%	3	-62.50%
Dec 31, 2025	17	-51.43%	4,827,731	-41.67%	15	2.13%	7	-22.22%	4	-63.64%
Sep 30, 2025	34	-	8,236,317	1.76%	27	3.79%	9	-40.00%	11	120.00%
Jun 30, 2025	36	-	8,284,557	-36.41%	27	1.46%	17	30.77%	5	-54.55%
Mar 31, 2025	37	-	14,340,830	-1.29%	47	2.01%	13	-45.83%	11	57.14%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	733.39K	2.04%	-
Vanguard Institutional Extnd Mkt Idx Tr	266.38K	0.74%	14.27K
Fidelity Extended Market Index	132.44K	0.37%	17.66K
Bridgeway Ultra-Small Company Market	59.00K	0.16%	-
iShares Micro-Cap ETF	53.52K	0.15%	-
Fidelity Total Market Index	48.50K	0.13%	-
BlackRock Extended Equity Market K	33.77K	0.11%	-14.00
Bridgeway Ultra-Small Company	33.20K	0.11%	33.20K
Extended Equity Market Fund B	38.75K	0.11%	-
Extended Equity Market Fund E	38.75K	0.11%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 29, 2026	Williams Sarah Joanne	Principal Accounting Officer	Sell	$1.17K
Mar 03, 2026	Williams Sarah Joanne	Principal Accounting Officer	Sell	$346.62
Jan 06, 2026	Day Lucy	Chief Financial Officer	Sell	$5.58K
Jan 05, 2026	Day Lucy	Chief Financial Officer	Sell	$3.30K
Jan 05, 2026	Prior Stephen David	Chief Strategy Officer	Sell	$3.61K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	-
2026 Q1	-	9
2025 Q4	-	2
2025 Q3	-	-
2025 Q2	2	5

ANTX Ownership FAQ

Who Owns AN2 Therapeutics?

AN2 Therapeutics shareholders are primarily institutional investors at 4.50%, followed by 18.87% insiders and 76.63% retail investors. The average institutional ownership in AN2 Therapeutics's industry, Biotech Stocks , is 35.98%, which AN2 Therapeutics falls below.

Who owns the most shares of AN2 Therapeutics?

AN2 Therapeutics’s largest shareholders are Vivo capital (3.15M shares, 10.44%), Commodore capital lp (2.33M shares, 7.72%), and Millennium management (2.22M shares, 7.36%). Together, they hold 25.52% of AN2 Therapeutics’s total shares outstanding.

Does Blackrock own AN2 Therapeutics?

BlackRock is not among the top 10 institutional shareholders of AN2 Therapeutics.

Who is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested?

Almitas capital is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.14% of its assets in 1.48M AN2 Therapeutics shares, valued at 5.06M$.

Who is the top mutual fund holder of AN2 Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of AN2 Therapeutics shares, with 2.04% of its total shares outstanding invested in 733.39K AN2 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools